Florida is currently home to 3838 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Recruiting
This early phase I pilot trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating patients with high-risk stage III melanoma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib, cobime... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Lysosomal Acid Lipase (LAL) Deficiency Registry
Recruiting
This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.
Gender:
All
Ages:
All
Trial Updated:
07/20/2023
Locations: Not set, Orlando, Florida
Conditions: Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, LIPA Deficiency, LAL-Deficiency
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Recruiting
The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Mayo Clinic Cancer Center, Jacksonville, Florida
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Autoimmune Encephalitis, Encephalitis
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
Recruiting
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Advent Health, Orlando, Florida
Conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
Recruiting
The purpose of this study is to evaluate the efficacy and safety of an adjuvant treatment of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with HER2-low expression (IHC 1+ or 2+ and ISH-) and hormone receptor-negative(ER-, PR-) breast cancer with residual disease after neoadjuvant treatment. Patients will be randomized 1:1 to either the Experimental arm (combination of AST-301/rhuGM CSF and standard adjuvant therapy) or the Control arm (combination of placebo/rhuGM CSF and stand... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
Recruiting
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2023
Locations: Qps-Mra, Llc., South Miami, Florida
Conditions: Healthy
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
Recruiting
This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Manatee Medical Research Institute, Bradenton, Florida
Conditions: Prostate Cancer
Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers
Recruiting
The goal of this project is to use genomic profiling, candidate genes and proteins to develop guided surgical debridement to improve healing in chronic non-healing venous leg ulcers (VLUs) and to test the efficacy of this approach.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: University of Miami, Miami, Florida
Conditions: Venous Leg Ulcer
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Recruiting
Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
07/18/2023
Locations: Memorial Healthcare System, Hollywood, Florida
Conditions: Chronic Kidney Disease; Iron Deficiency Anemia
Study to Assess PDM608 in Healthy Adult Subjects
Recruiting
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of PDM608 in healthy adult subjects.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/17/2023
Locations: Quotient Sciences-Miami, Inc, Miami, Florida
Conditions: Parkinson Disease